Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M
Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve ever seen.”
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Tarsus bets $450M on Alkeus’ Stargardt drug endpoints.news